Harvard Apparatus Regenerative Technology Q3 2026 diluted loss per share more than doubles to $0.58

• Harvard Apparatus Regenerative Technology’s third-quarter 2026 adjusted loss per share widened 50% year over year to $0.06.
• Revenue rose 8% year over year to $22.2 million, driven by strong sales to CROs and customers in China.
• Project Viking remains on track for completion by the end of the first quarter of 2027.
• FY26 adjusted EBITDA growth guidance fell to between a 1% decline and 4% growth, from 6%-10% growth.
• FY26 revenue growth guidance remained at 3%-5%, while fourth-quarter revenue is projected at $23.7 million-$25.5 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harvard Apparatus Regenerative Technology Inc. published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.